169 related articles for article (PubMed ID: 10999842)
1. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.
Maheshwari HG; Prezant TR; Herman-Bonert V; Shahinian H; Kovacs K; Melmed S
J Clin Endocrinol Metab; 2000 Sep; 85(9):3409-16. PubMed ID: 10999842
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
4. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
Resmini E; Dadati P; Ravetti JL; Zona G; Spaziante R; Saveanu A; Jaquet P; Culler MD; Bianchi F; Rebora A; Minuto F; Ferone D
J Clin Endocrinol Metab; 2007 May; 92(5):1592-9. PubMed ID: 17311860
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
6. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
7. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
8. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
[TBL] [Abstract][Full Text] [Related]
9. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
Tajima T; Tsubaki J; Ishizu K; Jo W; Ishi N; Fujieda K
Endocr J; 2008 Jul; 55(3):595-9. PubMed ID: 18445999
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
11. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
12. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
13. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
14. Effects of octreotide infusion, surgery and estrogen on suppression of height increase and 20K growth hormone ratio in a girl with gigantism due to a growth hormone-secreting macroadenoma.
Minagawa M; Yasuda T; Someya T; Kohno Y; Saeki N; Hashimoto Y
Horm Res; 2000; 53(3):157-60. PubMed ID: 11044798
[TBL] [Abstract][Full Text] [Related]
15. Cyproheptadine-mediated inhibition of growth hormone and prolactin release from pituitary adenoma cells of acromegaly and gigantism in culture.
Ishibashi M; Fukushima T; Yamaji T
Acta Endocrinol (Copenh); 1985 Aug; 109(4):474-80. PubMed ID: 2994332
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
17. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.
Mangupli R; Rostomyan L; Castermans E; Caberg JH; Camperos P; Krivoy J; Cuauro E; Bours V; Daly AF; Beckers A
Pituitary; 2016 Oct; 19(5):507-14. PubMed ID: 27287035
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
